TY - JOUR
T1 - In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria
AU - Piper, Kerryl E.
AU - Steckelberg, James M.
AU - Patel, Robin
N1 - Funding Information:
Acknowledgments Support provided by Cubist Pharmaceuticals (Lexington, MA, USA) and by the Mayo Foundation.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2005/9
Y1 - 2005/9
N2 - We determined the activity of daptomycin, a recently FDA-approved antimicrobial agent, against clinical isolates of Gram-positive bacteria, including viridans group streptococci (16 Streptococcus mitis species group, 12 S. mutans species group, 9 S. anginosus species group, 8 S. sanguinis species group, 5 S. salivarius species group) from patients with infective endocarditis, 32 methicillin-resistant Staphylococcus aureus, 32 high-level penicillin-resistant Streptococcus pneumoniae, 38 vancomycin-resistant enterococci (including 1 linezolid-resistant isolate), and thefollowing unusual Gram-positive bacteria: 3 Listeria monocytogenes, 4 Erysipelothrix rhusiopathiae, 9 Corynebacterium species, 10 Abiotrophia/Granulicatella species, 2 Rothia (Stomatococcus) mucilaginosus, and 4 Gemella morbillorum. Daptomycin minimum inhibitory concentration (MIC)90 values for the viridans group streptococci, methicillin-resistant S. aureus, penicillin-resistant S. pneumoniae, and Enterococcus species were 0.5, 0.5, ≤0.125, and 4μg/ml, respectively. The daptomycin MIC range for the unusual Gram-postitive bacteria was ≤0.125-2μg/ml. We conclude that daptomycin has in vitro activity against viridans group streptococci associated with endocarditis as well as against several types of unusual Gram-positive bacteria that can cause endocarditis.
AB - We determined the activity of daptomycin, a recently FDA-approved antimicrobial agent, against clinical isolates of Gram-positive bacteria, including viridans group streptococci (16 Streptococcus mitis species group, 12 S. mutans species group, 9 S. anginosus species group, 8 S. sanguinis species group, 5 S. salivarius species group) from patients with infective endocarditis, 32 methicillin-resistant Staphylococcus aureus, 32 high-level penicillin-resistant Streptococcus pneumoniae, 38 vancomycin-resistant enterococci (including 1 linezolid-resistant isolate), and thefollowing unusual Gram-positive bacteria: 3 Listeria monocytogenes, 4 Erysipelothrix rhusiopathiae, 9 Corynebacterium species, 10 Abiotrophia/Granulicatella species, 2 Rothia (Stomatococcus) mucilaginosus, and 4 Gemella morbillorum. Daptomycin minimum inhibitory concentration (MIC)90 values for the viridans group streptococci, methicillin-resistant S. aureus, penicillin-resistant S. pneumoniae, and Enterococcus species were 0.5, 0.5, ≤0.125, and 4μg/ml, respectively. The daptomycin MIC range for the unusual Gram-postitive bacteria was ≤0.125-2μg/ml. We conclude that daptomycin has in vitro activity against viridans group streptococci associated with endocarditis as well as against several types of unusual Gram-positive bacteria that can cause endocarditis.
KW - Antimicrobial resistance
KW - Daptomycin
KW - Endocarditis
KW - Enterococci
KW - Gram-positive bacteria
KW - Streptococci
UR - http://www.scopus.com/inward/record.url?scp=24044438472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24044438472&partnerID=8YFLogxK
U2 - 10.1007/s10156-005-0395-x
DO - 10.1007/s10156-005-0395-x
M3 - Article
C2 - 16133715
AN - SCOPUS:24044438472
SN - 1341-321X
VL - 11
SP - 207
EP - 209
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 4
ER -